200120172020

Addressing inequities in access to healthcare: 4 recommendations for biopharma manufacturers

Alisha Robert, Consultant | 16 November 2021

Hero image

In this market access update, Alisha Roberts, Consultant at PRMA Consulting (a member of Fishawack Health), explores the common barriers to accessing healthcare for minority, vulnerable, and excluded groups.

Read the full article to learn more about these 4 recommendations for pharmaceutical and biotechnology manufacturers seeking to address inequities in access to healthcare: 

  1. Use social determinants of health and electronic health records in forecasts of health outcomes.
  2. Help to address inequities in the social determinants of health.
  3. Ensure that clinical trial outcomes are representative of the entire population.
  4. Develop innovative collaborations with all stakeholders to determine value.

What does inequity in health mean?

When developing strategies for access to healthcare, the terms health inequality and inequity are sometimes confused or used interchangeably. They shouldn’t be, it’s important to recognize the difference between inequality and inequity:  

  • Inequality in health refers to the uneven distribution of health and/or resources due to factors such as genetics. 
  • Inequity in health refers to differences arising from social determinants such as governance or culture.

The 2 primary factors that contribute to inequities in health

The World Health Organization identifies two main clusters of root causes of health inequity.  

The first is the intrapersonal, interpersonal, institutional, and systemic mechanisms that impact access to healthcare differentially across race, gender, class, sexual orientation, gender expression, and other determinants of individual and group identity.  

The second is the unequal allocation of power and resources, including goods, services, and societal attention, which result in unequal social, economic, and environmental conditions. These are called the social determinants of health.

Read the full article on the PRMA Consulting website

Latest articles

ICER and Value Assessment Frameworks: 5 key insights for biopharma

30 November 2021

Fishawack Gives Back: How we’re mobilizing our teams to support philanthropic causes across the globe

23 November 2021

Fishawack Health welcomes FIDE, a leading network of dermatology experts, to its group

10 November 2021

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on fishawack.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Fishawack.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.